AUGUSTA, Ga. - A new protein identified as critical to insulating the wiring that connects the brain and body could one day be a treatment target for divergent diseases, from rare ones that lower the pain threshold to cancer, Medical College of Georgia researchers say.
They report this week in Proceedings of the National Academy of Sciences Online Early Edition that in the peripheral nervous system that controls arms and legs, the protein erbin regulates the protein neuregulin 1, stabilizing and interacting with the ErbB2 receptor on Schwann cells so they can make myelin, which insulates the wiring.
Their studies in mice have shown that when erbin is missing or mutated, the insulation is inadequate, slowing communication.
"Erbin is like a tuner to make signaling stronger or weaker," says Dr. Lin Mei, the study's corresponding author and director of MCG's Institute of Molecular Medicine and Genetics.
Without erbin, the myelin production system falls apart. Eventually raw, over-exposed nerves can die.
"Receptors for neuregulin 1 just get degraded and lost," says Dr. Mei, Georgia Research Alliance Eminent Scholar in Neuroscience. "Schwann cells can see neuregulin 1 sitting there but they can't do anything without the receptor."
Impaired myelin formation and maintenance is implicated in a variety of neurological and psychiatric diseases including schizophrenia, multiple sclerosis and Charcot-Marie-Tooth neuropathy, a genetic, progressive disease that weakens muscles.
Cancer is an issue because the ErbB2 receptor also is an oncogene highly expressed in tumors. ErbB2 helps cancer cells grow and spread so finding its role in the receptor's stability and function provides a potential new site for targeted cancer therapy, says Dr. Yanmei Tao says, postdoctoral fellow in neurobiology and the study's first author. In fact, antibodies to ErbB2 already are available to patients with breast and prostate
|Contact: Toni Baker|
Medical College of Georgia